Provenge (Prostate Cancer) - Forecast and Market Analysis to 2022


#163789

52pages

GlobalData

$ 6995

In Stock

Provenge (Prostate Cancer) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report,  Provenge (Prostate Cancer) - Forecast and Market Analysis to 2022. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Dendreon’s Provenge is the first FDA-approved therapeutic cancer vaccine, and is a treatment for mCRPC. It consists of the patient’s own immune cells, which have been activated against Prostatic Acid Phosphatase (PAP), a protein found in prostate cancer cells (Provenge Prescribing Information, 2011). These activated immune cells are then infused back into the patient and induce an immune response against the prostate cancer cells.

Scope
  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Provenge including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Provenge for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Provenge performance 
  • Obtain sales forecast for Provenge from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.1.3 Prognosis 12
3.1.4 Quality of Life 13
3.2 Symptoms 14

4 Disease Management 15
4.1 Diagnosis and Referral Overview 15
4.2 Treatment Overview 17
4.2.1 Conservative Management Strategies 22
4.2.2 Localized Treatments 23
4.2.3 Hormone Therapy 24
4.2.4 Drug Therapies 26

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29

6 Provenge (sipuleucil-T) 32
6.1 Overview 32
6.2 Efficacy 34
6.3 Safety 35
6.4 SWOT Analysis 35
6.5 Forecast 38

7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 43
7.3 Methodology 45
7.4 Forecasting Methodology 45
7.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 45
7.4.2 Percent Drug-treated Patients 46
7.4.3 Percent Hormone Therapy-Treated Patients 46
7.4.4 General Pricing Assumptions 46
7.4.5 Individual Drug Assumptions 48
7.4.6 Generic Erosion 49
7.5 Physicians and Specialists Included in This Study 49
7.6 Survey of Prescribing Physicians 50
7.7 About the Authors 51
7.7.1 Authors 51
7.7.2 Global Head of Healthcare 51
7.8 About GlobalData 52
7.9 Contact Us 52
7.10 Disclaimer 52

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 13
Table 2: Global Variations in Recommendations on Routine PSA Screening 15
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 18
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 21
Table 5: Leading Treatments for Prostate Cancer, 2012 31
Table 6: Product Profile - Provenge 32
Table 7: Provenge SWOT Analysis, 2012 37
Table 8: Global Sales Forecasts ($m) for Provenge, 2012-2022 38
Table 9: Physicians Surveyed, By Country 50
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 20